Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 174-180, January 1, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prior, T. I.
Right arrow Articles by Pastan, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prior, T. I.
Right arrow Articles by Pastan, I.

Cytotoxic Activity of a Recombinant Fusion Protein between Insulin-like Growth Factor I and Pseudomonas Exotoxin

Trevor I. Prior, Lee J. Helman, David J. FitzGerald and Ira Pastan1

Laboratory of Molecular Biology, DCBDC [T. I. P., D. J. F., I. P.], and Pediatric Branch, Division of Cancer Treatment [L. J. H.], National Cancer Institute, NIH, Bethesda, Maryland 20892

A chimeric toxin in which the cell binding domain of Pseudomonas exotoxin was replaced with mature human insulin-like growth factor I (IGF-I) was produced in Escherichia coli. This protein, IGF-I-PE40, was cytotoxic to human cell lines derived from a variety of tumor types, with a breast carcinoma line (MCF-7) and two hepatoma lines (HEP3B and HEPG2) showing the highest sensitivity to the toxin. The specificity of IGF-I-PE40 cytotoxicity was confirmed through competition with excess IGF-I and through blockage of toxin binding using an antibody specific to the type I IGF receptor. A potential interaction between the toxin and soluble IGF-binding proteins was also demonstrated. IGF-I-PE40 may be useful in the selective elimination of cells bearing the type I IGF receptor.

1 To whom requests for reprints should be addressed.

Received 8/ 8/90. Accepted 10/ 9/90.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Kawakami, K. Kawakami, V. A. Stepensky, R. A. Maki, H. Robin, W. Muller, S. R. Husain, and R. K. Puri
Interleukin 4 Receptor on Human Lung Cancer: A Molecular Target for Cytotoxin Therapy
Clin. Cancer Res., November 1, 2002; 8(11): 3503 - 3511.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
I Pastan and D FitzGerald
Recombinant toxins for cancer treatment
Science, November 22, 1991; 254(5035): 1173 - 1177.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.